Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinopharm Affiliate Pays $6.5 Million Milestone to Oramed

publication date: Jun 22, 2016
Hefei Tianhui Incubator of Technologies, a Sinopharm affiliate, made a $6.5 million milestone payment to Oramed Pharma as part of HTIT's in-licensing of Oramed's oral insulin product. Oramed recently announced positive top-line results from a US Phase II trial of the product in patients with type 2 diabetes. In November 2015, HTIT agreed to a $50 million package for China rights to the Oramed's oral insulin. HTIT is partially owned by China's giant state-owned Sinopharm. More details....

Stock Symbol: (NSDQ: ORMP)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital